Skip to main content

Table 4 Estimates of lead time of lung cancer (years) by methods of study

From: Duration of lead time in screening for lung cancer

Estimates derived from

From cytological to clinical

From low dose computed tomography to clinical

From radiographic to clinical

Follow up (longitudinal studies)

2.5a

 

0.8–1.1

Prevalence / incidence ratios all histologic types

 

1.1–3.5

0.6–2.1

Prevalence / incidence ratios squamous cell cancer only

1.3–1.5

 

1.2–1.8b

Doubling time, all histologic types

 

3.9c

0.2d

Doubling time, squamous cell lung cancer only

2.1e

1.0f

0.14g

Statistical methods applied on controlled trials (modes and range of probability density curves, and means and standard errors)

 

Mode: 0.9 (0–3.0)

Mean: 0.87 (0.69)

Mode: 0.24 (0–2.0)

Mean: 1.0 (1.7)

  1. aTime interval between carcinoma in situ and invasive carcinoma
  2. bCalculated from the data reported by Doria-Rose et al. 2009 [11] on the prevalence and incidence of squamous cell cancers detected by CR
  3. cAssuming a doubling time of 480 days [27]
  4. dAssuming a doubling time of 150 days [27]
  5. eAssuming a doubling time of 104 days [27]
  6. fAssuming a doubling time of 122 days [27]
  7. gAssuming a doubling time of 105 days [27]
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us